| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP, Chf Gl Pdt Str & Oper Ofc | EVP, Chf Pdt Str & Oper Ofc +2 more
2 companies
Onaiza Cadoret-Manier is Director at ARDX, with reported holdings spanning 2 companies. Onaiza Cadoret-Manier's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.0M at current prices.
Our model assigns Onaiza Cadoret-Manier a middling insider score of 53/100, based on 5 past trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of +2.4%.
Onaiza Cadoret-Manier's largest disclosed position is in IONS as EVP, Chf Gl Pdt Str & Oper Ofc, worth about $1.4M. The IONS filings lean toward selling, a net 15,470 shares.
Onaiza Cadoret-Manier has 33 Form 4 filings on record from January 2020 to June 2026, across 3 companies: Director at Ardelyx (ARDX), 2020–2026; Director at Ventyx Biosciences (VTYX), 2023–2025; EVP, Chf Gl Pdt Str & Oper Ofc at Ionis Pharmaceuticals (IONS), 2020–2024.
The 48 reported transactions were 25 option or other derivative awards, 7 stock awards, 6 option exercises and 5 open-market sales, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 5 sales worth about $687K.
The largest open-market sale was 5,564 shares of IONS at an average $50.42 on January 17, 2024, about $281K. Twelve months later IONS was down 37%.
None of the 3 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 2, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Gl Pdt Str & Oper Ofc | Sell | 2,125 | $49.60 | $105,404.25 | -5.6% | -13.4% | -35.9% | |
| Jan 17, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Gl Pdt Str & Oper Ofc | Sale+OE | 5,564 | $50.42 | $280,520.19 | -14.1% | -19.0% | -37.1% | |
| Apr 18, 2023 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Gl Pdt Str & Oper Ofc | Sale+OE | 2,582 | $36.50 | $94,249.71 | -9.6% | +16.0% | +12.5% | |
| Feb 6, 2023 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Gl Pdt Str & Oper Ofc | Sell | 1,451 | $40.66 | $58,996.93 | -6.4% | -13.1% | +21.3% | |
| Jan 18, 2023 | IONS Ionis Pharmaceuticals Inc | EVP, Chf Gl Pdt Str & Oper Ofc | Sale+OE | 3,748 | $39.55 | $148,223.28 | -16.8% | -8.6% | +27.2% |